BR112016021345A2 - - Google Patents
Info
- Publication number
- BR112016021345A2 BR112016021345A2 BR112016021345A BR112016021345A BR112016021345A2 BR 112016021345 A2 BR112016021345 A2 BR 112016021345A2 BR 112016021345 A BR112016021345 A BR 112016021345A BR 112016021345 A BR112016021345 A BR 112016021345A BR 112016021345 A2 BR112016021345 A2 BR 112016021345A2
- Authority
- BR
- Brazil
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/50—Vectors comprising a special translation-regulating system utilisation of non-ATG initiation codon
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461954588P | 2014-03-17 | 2014-03-17 | |
| PCT/US2015/021117 WO2015142963A1 (en) | 2014-03-17 | 2015-03-17 | Nucleic acid molecule vaccine compositions and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016021345A2 true BR112016021345A2 (US07943777-20110517-C00090.png) | 2017-10-03 |
| BR112016021345A8 BR112016021345A8 (pt) | 2022-07-05 |
Family
ID=52774612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016021345A BR112016021345A8 (pt) | 2014-03-17 | 2015-03-17 | Composições de vacina de molécula de ácido nucleico e usos das mesmas |
Country Status (8)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2975816A1 (en) | 2015-05-15 | 2016-11-24 | Curevac Ag | Prime-boost regimens involving administration of at least one mrna construct |
| EP3377516B1 (en) | 2015-11-20 | 2022-06-15 | Memorial Sloan Kettering Cancer Center | Composition for treating cancer |
| US11723962B2 (en) | 2016-05-04 | 2023-08-15 | Fred Hutchinson Cancer Center | Cell-based neoantigen vaccines and uses thereof |
| US11104916B2 (en) | 2016-07-15 | 2021-08-31 | Etubics Corporation | Compositions and methods for alphavirus vaccination |
| CA3030447A1 (en) | 2016-07-15 | 2018-01-18 | Etubics Corporation | Compositions and methods for flavivirus vaccination |
| AU2017362730B2 (en) * | 2016-11-21 | 2021-04-08 | Nant Holdings Ip, Llc | Fractal combination therapy |
| CN117224710A (zh) | 2017-02-01 | 2023-12-15 | 莫得纳特斯公司 | 编码活化致癌基因突变肽的免疫调节治疗性mrna组合物 |
| US20200345800A1 (en) * | 2017-10-03 | 2020-11-05 | Tokyo Metropolitan Institute Of Medical Science | Medication for influenza |
| US20210071149A1 (en) * | 2017-12-19 | 2021-03-11 | Akouos, Inc. | Aav-mediated delivery of therapeutic antibodies to the inner ear |
| CN110117675B (zh) * | 2018-02-05 | 2022-03-04 | 西比曼生物科技（香港）有限公司 | 一种实时荧光定量pcr检测rcl的试剂和方法 |
| CN108619499A (zh) * | 2018-04-17 | 2018-10-09 | 南昌大学 | 一种结核病疫苗及其制备工艺 |
| CN110144334B (zh) * | 2019-05-05 | 2021-03-16 | 中国水产科学研究院长江水产研究所 | 一种共表达草鱼呼肠孤病毒外衣壳蛋白vp4和vp35的重组杆状病毒的制备方法和应用 |
| CN111330002B (zh) * | 2020-03-09 | 2020-12-01 | 北京鼎成肽源生物技术有限公司 | 靶向冠状病毒的通用dc细胞疫苗及其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| US6028058A (en) * | 1997-07-21 | 2000-02-22 | Ciblex Corporation | Methods and compositions for regulating nuclear trafficking of proteins |
| US6709863B2 (en) | 1999-12-08 | 2004-03-23 | Iowa State University Research Foundation | Nucleic acid molecules encoding multiple start codons and histidine tags |
| US20110111413A1 (en) | 2001-02-02 | 2011-05-12 | Padgett Hal S | Method of optimizing codon usage through dna shuffling |
| KR20050083719A (ko) | 2002-10-03 | 2005-08-26 | 에피뮨 인코포레이티드 | 최적화된 멀티-에피토프 구성체 및 이의 용도 |
| CA2685300C (en) | 2006-06-01 | 2017-01-03 | Mayo Foundation For Medical Education And Research | Immunity to folate receptors |
| KR20140022430A (ko) | 2006-11-30 | 2014-02-24 | 탭이뮨, 인크. | 분자 아주반트로서 ｔａｐ―１ 및/또는 ｔａｐ―２를 포함하는 폭스비리대 치료 |
| US20080292918A1 (en) | 2007-05-25 | 2008-11-27 | Caine Finnerty | Electrochemical system having multiple independent circuits |
| WO2009059011A2 (en) | 2007-11-01 | 2009-05-07 | Mayo Foundation For Medical Education And Research | Hla-dr binding peptides and their uses |
| WO2010096693A2 (en) * | 2009-02-19 | 2010-08-26 | Mayo Foundation For Medical Education And Research | Methods and materials for generating t cells |
| EA025280B1 (ru) * | 2010-03-09 | 2016-12-30 | Амир Максютов | Полиэпитопные конструкции и способы их получения и применения |
| MX2016005656A (es) | 2013-11-01 | 2016-07-14 | Pfizer | Vectores para expresion de antigenos asociados a prostata. |
-
2015
- 2015-03-17 JP JP2017501087A patent/JP2017510297A/ja active Pending
- 2015-03-17 WO PCT/US2015/021117 patent/WO2015142963A1/en active Application Filing
- 2015-03-17 CN CN201580023035.XA patent/CN106459992A/zh active Pending
- 2015-03-17 AU AU2015231461A patent/AU2015231461B2/en not_active Ceased
- 2015-03-17 BR BR112016021345A patent/BR112016021345A8/pt not_active Application Discontinuation
- 2015-03-17 US US14/660,924 patent/US9364523B2/en active Active
- 2015-03-17 CA CA2942501A patent/CA2942501A1/en active Pending
- 2015-03-17 EP EP15713123.6A patent/EP3119893A1/en not_active Withdrawn
-
2016
- 2016-06-13 US US15/180,852 patent/US9988643B2/en not_active Expired - Fee Related
- 2016-07-28 US US15/222,627 patent/US10030252B2/en active Active
- 2016-07-28 US US15/222,619 patent/US9655956B2/en not_active Expired - Fee Related
-
2018
- 2018-01-29 US US15/882,724 patent/US20180163226A1/en not_active Abandoned
- 2018-01-29 US US15/882,626 patent/US20180230487A1/en not_active Abandoned
-
2019
- 2019-09-17 JP JP2019168454A patent/JP2019205482A/ja active Pending
-
2021
- 2021-03-01 US US17/189,120 patent/US20220033844A1/en active Pending
- 2021-04-05 US US17/222,910 patent/US20220056473A1/en active Pending
- 2021-12-08 AU AU2021282438A patent/AU2021282438A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20220033844A1 (en) | 2022-02-03 |
| US20220056473A1 (en) | 2022-02-24 |
| US9655956B2 (en) | 2017-05-23 |
| WO2015142963A1 (en) | 2015-09-24 |
| CN106459992A (zh) | 2017-02-22 |
| EP3119893A1 (en) | 2017-01-25 |
| US20160367652A1 (en) | 2016-12-22 |
| US9364523B2 (en) | 2016-06-14 |
| US20160354455A1 (en) | 2016-12-08 |
| JP2019205482A (ja) | 2019-12-05 |
| US20150258186A1 (en) | 2015-09-17 |
| CA2942501A1 (en) | 2015-09-24 |
| US10030252B2 (en) | 2018-07-24 |
| US9988643B2 (en) | 2018-06-05 |
| US20180163226A1 (en) | 2018-06-14 |
| US20180230487A1 (en) | 2018-08-16 |
| BR112016021345A8 (pt) | 2022-07-05 |
| US20170016026A1 (en) | 2017-01-19 |
| JP2017510297A (ja) | 2017-04-13 |
| AU2021282438A1 (en) | 2021-12-23 |
| AU2015231461A1 (en) | 2016-10-06 |
| AU2015231461B2 (en) | 2021-09-09 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: MARKER THERAPEUTICS, INC. (US) |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |